Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor

Anna Maria Orengo, Marina Fabbi, Loredana Miglietta, Cristian Andreani, Milena Bruzzone, Andrea Puppo, Paolo Cristoforoni, Maria Grazia Centurioni, Marina Gualco, Sandra Salvi, Simona Boccardo, Mauro Truini, Tiziana Piazza, Silvana Canevari, Delia Mezzanzanica, Silvano Ferrini

Research output: Contribution to journalArticle

Abstract

Interleukin (IL)-18 is a proinflammatory and immune-enhancing cytokine, which exerts antitumor effects in vivo, mediated by the induction of interferon (IFN)γ. We previously reported that IL-18 processing is defective in epithelial ovarian carcinoma (EOC) cells, which secrete an inactive precursor (pro-IL-18) in vitro. In addition, IL-18 was reported as a potential biomarker of EOC. Here, we further investigated its role as a serological marker in human EOC and addressed its possible biological activity in vivo. Our data indicate that immunoreactive IL-18 is increased in EOC patients' sera at diagnosis as compared with age-matched healthy women. IL-18 levels were higher in the ascitic fluids than in sera, suggesting a local production in the peritoneal cavity. Indeed, immunohistochemical analysis of tumors showed IL-18 expression in cytokeratine-positive neoplastic cells, although also scattered histiocytes and some lymphoid cells stained for IL-18. The detection of human IL-18 in sera and ascitic fluids of immunodeficient mice, orthotopically implanted with human EOC cells, further suggested that circulating IL-18 is tumor-derived. However, IL-18 is not an EOC specific biomarker, as increased serum levels were found also in some endometrial cancer patients. By means of a new monoclonal antibody, we characterized IL-18 present in the ascitic fluid as pro-IL-18, which is biologically inactive. Accordingly, IFNγ was not increased in EOC patients' sera and ascitic fluids and showed no correlation with IL-18 levels. Altogether these data indicate that IL-18 in EOC fluids is predominantly tumor-derived and that its lack of biological activity may represent a mechanism of tumor-escape.

Original languageEnglish
Pages (from-to)1116-1125
Number of pages10
JournalInternational Journal of Cancer
Volume129
Issue number5
DOIs
Publication statusPublished - Sep 1 2011

Keywords

  • biomarker
  • IL-18
  • immature precursor
  • ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor'. Together they form a unique fingerprint.

  • Cite this

    Orengo, A. M., Fabbi, M., Miglietta, L., Andreani, C., Bruzzone, M., Puppo, A., Cristoforoni, P., Centurioni, M. G., Gualco, M., Salvi, S., Boccardo, S., Truini, M., Piazza, T., Canevari, S., Mezzanzanica, D., & Ferrini, S. (2011). Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. International Journal of Cancer, 129(5), 1116-1125. https://doi.org/10.1002/ijc.25757